David J. Stanoch

David joined the firm in August 2020 as Counsel, and is part of Kanner & Whiteley’s complex litigation team.  He focuses his practice on complex class actions as well as mass torts and mass litigation.  David has extensive experience representing clients in complicated matters involving antitrust, consumer fraud, product liability, and white collar issues.  He manages cases from preliminary investigation through trial and settlement.  He has taken lead roles in deposing corporate and individual witnesses in federal litigation, expert preparation and depositions, and negotiating with government investigators. He also has extensively briefed discovery and merits issues from the pretrial stage forward, and has made substantial contributions towards posturing cases for favorable settlements.

Prior to joining Kanner & Whiteley, David worked at a boutique plaintiffs’ litigation firm in Philadelphia, Pennsylvania.  He was also an associate at Dechert LLP for nearly ten years. While there, he advised Fortune 50, 100, and 200 clients on matters pertinent to complex and multi-district litigation, federal and state government investigations, and regulatory matters. He has represented individuals and companies in many industries, including: pharmaceuticals, biologics, banking and consumer finance, chemicals, food & agriculture, forest products, healthcare, mortgages, and construction materials.  Prior to that, David had clerked for federal district court judge, the Hon. James F. McClure, Jr. (dec.) (M.D. Pa.).

David has long-volunteered as a pro bono attorney, representing diverse clients in need of legal representation, such as representing students with disabilities, or serving as a court-appointed guardian ad litem attorney on behalf of dependent or adoptive children in family court.

He is licensed to practice in Pennsylvania and New Jersey, and is admitted to practice before the U.S. Court of Appeals for the Third Circuit, the U.S. Court of Appeals for the Sixth Circuit, the U.S. District Court for the Eastern District of Pennsylvania, the U.S. District Court for the Middle District of Pennsylvania, U.S. District Court for the Western District of Pennsylvania, admitted 02/2021, and the U.S.
District Court for the District of New Jersey.

Representative Matters

In re Valsartan, Losartan, & Irbesartan Products Liability Litigation, MDL No. 2875 (D.N.J.),

Moore v. Angie’s List, Inc., No. 15-cv- 2413 (E.D. Pa.)

Brill v. Bank of America, N.A., No. 16-cv-3817 (D. Ariz.)

Krimes v. JPMorgan Chase Bank, N.A., No. 15- cv-5087 (E.D. Pa.)

In re Intuniv Antitrust Litigation, No. 16-cv-12395 (D. Mass.)

Barba, et al. v. Shire US, Inc., et al., No. 11-cv-21158 (S.D. Fla.)

In re Testosterone Replacement Therapy Products Liability Litigation, MDL No. 2545 (N.D. Ill.)

Selected Publications, Lectures, or Honors

  • Author, “Pay day – a consortium of US drug companies have been ordered to pay $70m to California over pay-for-delay deals,” Intellectual Property Magazine (Oct. 2019)
  • Contributing Author, “Agriculture and Food Handbook,” ABA Section of Antitrust Law Publication Series (Mar. 2019)
  • Contributing Author (Chapter One), “Antitrust Law Developments (Seventh),” ABA Section of Antitrust Law Publication Series (Apr. 2012)
  • Co-Author, “Hiring Practices Can Be An Antitrust Violation?,” Corporate Counsel (Feb. 15. 2012)
  • Author, “When Reason Prevails: The Sixth and Ninth Circuits’ Recent Applications of the Rule of Reason Over Per Se or Quick Look Analyses,” ABA Antitrust Section Joint Committee E-Bulletin, Vol. 9, No. 1 (Fall 2011)
  • Co-Author, “It’s a Jungle Out There:  Animal Science Ruling Highlights Need for Strict Application of Twombly to Claims Subject to FTAIA,” BNA Antitrust & Trade Regulation Report (Dec. 2, 2011)
  • Co-Author, “United States Supreme Court Poised to Rule on the Regulatory Defence in a Pharmaceutical Case,” The International Comparative Legal Guide to Pharmaceutical Advertising 2008 (July 2008)
  • Co-Author, “Initial Recognition of the ‘Regulatory Defence’ by a United States Court in a Pharmaceutical Case,” The International Comparative Legal Guide to Pharmaceutical Advertising 2007 (July 2007)
  • Author, “Lawyers’ Obligations Regarding Inadvertent Disclosures,” Temple Law Review, 75 TEMPLR 657 (2002)
  • Numerous continuing legal education and training programs for clients and internal audiences, including:
  • Co-Presenter, “Daubert Motions” (May 29, 2013)
  • Co-Presenter, “Expert Depositions” (May 13, 2013)
  • Co-Presenter, “Everything You Wanted to Know About Antitrust Law…But Were Afraid To Ask” (Apr. 26, 2013)
  • Co-Presenter, “Daubert Motions” (May 30, 2012)
  • Co-Presenter, “Expert Depositions” (May 7, 2012)
  • Co-Presenter, “How to Select and Prepare Expert Witnesses” (Apr. 27, 2012)
  • Co-Presenter, “Preparation of Witness Kits” (Apr. 10, 2012)
  • Co-Presenter, “Business Conduct Giving Rise to Potential Antitrust Liability” (Sept. 9, 2011)
  • Co-Presenter, “Antitrust, Consumer Fraud and Electronic Discovery/Data Issues – A Pertinent Primer and Update” (June 3, 2011)
  • Co-Presenter, “How Antitrust Lawyers Practice Their Craft” (Mar. 2, 2010)